Sunday 18 October 2026
Export IVF’s income statement to Excel — free account
INVO Fertility, Inc
IVF Healthcare Medical Devices
INVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS grew 100.1%, free cash flow grew 35.1% and total debt fell 50.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.56
0.03
−5.08%
Follow IVF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.38 | 0.06 | 0.62 | 0.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.48) | 17.50 | (2.32) | (3.63) | |
P/B ratio |
0.00 | 0.09 | 0.30 | 0.25 | |
Price to Tangible BV |
0.00 | 0.00 | 0.66 | 0.73 | |
EV/Sales |
0.48 | (0.11) | 0.05 | 0.12 | |
EV/EBITDA |
0.00 | 0.14 | 0.00 | 0.00 | |
EV/Operating CF |
(0.44) | 0.11 | (0.07) | (0.20) | |
EV/FCF |
(0.43) | 0.11 | (0.07) | (0.19) | |
Quick Ratio |
0.07 | 0.22 | 0.81 | 0.61 | |
Current Ratio |
0.12 | 0.27 | 0.90 | 0.71 | |
Net Debt/EBITDA |
(0.43) | 5.91 | 2.93 | 2.81 | |
Debt/Assets |
5.85% | 3.68% | 2.68% | 1.99% | |
Debt/Equity |
0.19 | 0.10 | 0.04 | 0.03 | |
Asset Turnover |
0.39 | 0.21 | 0.26 | 0.33 | |
Operating CF/Net income |
0.67 | (0.02) | 0.35 | (1.24) | |
Capex/Depreciation |
0.10 | (0.01) | 0.00 | (0.13) | |
Interest Coverage |
(11.22) | (3.46) | (8.82) | (7.28) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
121.11% | 114.49% | 107.98% | 87.65% | |
Intangible Assets out of Total Assets |
0.39 | 0.36 | 0.32 | 0.41 | |
Share Based Compensation of Revenue |
27.40% | 8.86% | 3.52% | 1.12% | |
Graham Net Nets |
(4.52) | (23.20) | (0.87) | (1.18) | |
Graham Number |
1,578.39 | 1,220.36 | 790.11 | 791.09 | |
Earnings Yield |
(10,366.64%) | 42,636.66% | 114,256.32% | 191,589.05% | |
Free Cash Flow Yield |
(296.49%) | (1,600.54%) | (121.90%) | (120.45%) | |
Revenue per Share |
20.38 | 13.53 | 1.23 | 1.03 | |
Operating CF per Share |
(20.61) | 0.22 | (1.17) | (0.52) | |
Capex per Share |
(0.09) | (0.10) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(20.70) | 0.11 | (1.17) | (0.53) | |
Cash per Share |
4.13 | 17.76 | 2.99 | 1.77 | |
Shareholders Equity per Share |
67.85 | 61.75 | 9.17 | 7.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
67.85 | 61.75 | 9.17 | 7.83 | |
Free Cash Flow |
(1.78) | 0.01 | (1.92) | (1.12) | |
Working Capital |
(8.11) | (7.57) | (0.62) | (1.92) | |
Capital Expenditures |
(0.01) | (0.01) | — | (0.02) | |
Net Current Asset Value |
(11.85) | (10.23) | (3.90) | (4.74) | |
EV/EBIT |
0.00 | 0.10 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.27 | 0.17 | 0.21 | 0.25 | |
Average Payables |
2.52 | 2.57 | 3.23 | 1.91 | |
Average Inventory |
0.22 | 0.22 | 0.22 | 0.23 | |
Average Assets |
17.93 | 33.15 | 28.20 | 22.58 | |
Average Common Equity |
(5.35) | (6.49) | (6.21) | 4.30 |
Columns are period end dates